Provided by Integrity Continuing Education.
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.
Until recently the only treatment choices for patients with CRSwNP, a chronic inflammatory condition of the sinonasal cavities, included saline irrigation for symptomatic relief, local or oral corticosteroids to keep inflammation under control, and polypectomy through endoscopic sinus surgery. Of the upper inflammatory disorders, perhaps the most recalcitrant and refractory is CRSwNP. Nasal polyposis is typically present in patients with the highest levels of disease severity, and endoscopic surgery to remove polyps is not the cure one might presume. Nearly 80% of patients who undergo polypectomy experience polyp recurrence within two years and >35% eventually opt for a second surgery.
Novel biologics that were successful in controlling some forms of severe asthma were put into clinical trials to evaluate their impact on CRSwNP. Availability of biologics for CRSwNP gives clinicians treatment options beyond steroids and surgery for their CRSwNP patients who are struggling to breathe freely. However, it also confronts them with new and different decisions. What criteria should be used in choosing which CRSwNP patients should be prescribed a biologic? Which one should be tried and why? What did clinical trials reveal about their efficacy and safety in CRSwNP? How do I educate and prepare patients for treatment with a biologic? This program is designed to address these and other questions related to the treatment of patients with CRSwNP.
Cecelia C. Damask, DO
Assistant Clinical Professor
Department of Otolaryngology
University of Central Florida
Orlando, Florida
Christine B. Franzese, MD
Professor, Director of Allergy
Department of Otolaryngology
University of Missouri – Columbia
Columbia, Missouri
Robert M. Naclerio, MD
Otolaryngology-Head and Neck Surgery
Johns Hopkins University
Baltimore, Maryland
This educational activity has been designed to meet the needs of otolaryngologists, otolaryngic allergists, and nurse practitioners and physician assistants in otolaryngology specialty practice
Upon completion of this educational activity, participants should be able to:
There are no fees for participating and receiving CME credit for this activity. During the period of November 19, 2021 and November 19, 2022 participants must:
A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.
Internet
Physician Continuing Education
Accreditation Statement
Integrity Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Integrity Continuing Education designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or cme@integrityce.com.
Integrity Continuing Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The following faculty/planners reported the financial relationships or relationships to products or devices they have with commercial interests related to the content of these CME activities:
Cecelia C. Damask, DO
Advisory Board: AstraZeneca, Genentech/Novartis, GlaxoSmithKline, Optinose, Regeneron/Sanofi
Consultant: Audigy Medical
Contracted Clinical Research: AstraZeneca, GlaxoSmithKline, Optinose, Regeneron/Sanofi
Speakers Bureau: ALK, AstraZeneca, Genentech/Novartis, GlaxoSmithKline, Optinose, Regeneron/Sanofi
Christine B. Franzese, MD
Advisory Board: GlaxoSmithKline, Sanofi
Research Funding: ALK, Bellus, GlaxoSmithKline, Merck, Novartis, Regeneron, Sanofi, Shiniogi
Speakers Bureau: ALK, Genentech, GlaxoSmithKline, Novartis, Regeneron, Sanofi
Robert M. Naclerio, MD
Advisory Board: AstraZeneca, Celgene, GlaxoSmithKline, Lyra Therapeutics, Regeneron, Sanofi
The Integrity Continuing Education planners and managers have nothing to disclose.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education does not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
When you participate in an online educational activity sponsored by Integrity Continuing Education, you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)
Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe® Flash® Player 10
For optimal performance, the use of Internet Explorer below 8 is not recommended
For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements
The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.